The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012

This publication has been discontinued on August 12, 2011.

Introduction

Abstract

' The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new report from visiongain providing analysis of the current and future market for IBD drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global IBD market. Autoimmune disease is a multimillion dollar market set to increase as world prevalence rates rise and the population lives longer. Inflammatory bowel disease (IBD) affect millions of people worldwide with 2.8 million currently diagnosed with ulcerative colitis (UC) or Crohn' s disease (CD) in the US alone. The incidence of IBD is rising in developing countries around the world. Currently the global market is estimated at $16bn and this is set to continue to rise.

Historically, management of IBD with sulphonamides and corticosteroids did little to alter the course of disease and had severe side effects. In the 1990' s new therapies were introduced in the form of enteric coated aminosalicylates (5-ASA). From 3 drugs and one target in 1993 there are now more than 30 products and 10 targets. With the advent of monoclonal antibodies for use in IBD there has been a breakthrough in disease management which is set to expand rapidly over the next few years. Many more expensive biologicals are in the pipeline. As they gain approval and are prescribed in favour of cheaper options, revenues in the IBD market will grow rapidly.

• Will the current monoclonal blockbuster used to treat IBD continue to grow?
• What are the hottest research drugs in the pipeline?
• Will safety of issues restrict the use of biological agents in IBD?

Buy this report to find out!

Included in this report:

This report includes an up-to-date, analysis of IBD including the current market and possible future developments. The following important issues are covered in detail:

What new anti-inflammatory drugs are seeking the IBD indication Unique analysed forecast for the biologicals market for IBD, 2007-2012 Summaries and revenue forecasts for the leading 5-ASA drugs, 2007-2012 Summaries and revenue for monoclonal antibody drugs, 2007-2012 A thorough examination of the biological pipeline for IBD including cytokine, chemokine and adhesion molecule antagonists An assessment of future developments You must order this report today.

Unique benefits to you when you order this report:

• Full searchable report when you buy the company or corporate editions
• Immediate access through our exclusive Reading Room
• You can access your report whichever country you are in without using harddrive space
• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables

If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.

Table of Contents

Chapter 1. Executive Summary

• 1.1 Aims of This Report
• 1.2 Summary and Contents

Chapter 2. Introduction

• 2.1 Immunity and Self Preservation
  • 2.1.1 Innate immunity
  • 2.1.2 Adaptive immunity
• 2.2 Autoimmune Disease, Antigens and Autoantibodies
  • 2.2.1 Antigens
  • 2.2.2 Autoantibodies
• 2.3 Inflammation, Regulation and Central Matrix Destruction
• 2.4 Adhesion Molecules, Cytokines and Chemokines
  • 2.4.1 Adhesion Molecules
  • 2.4.2 Cytokines
  • 2.4.3 Chemokines
  • 2.4.4 Orchestral Role of Cytokines - Primary Focus for Research
• 2.5 Aetiology of AI Disease
• 2.6 Spectrum of Autoimmune Disease
  • 2.6.1 Organ-Specific AI Disease
  • 2.6.2 Non-Organ Specific AI Disease

Chapter 3. Autoimmune Disease and the Anti-inflammatory Market

• 3.1 World Sales of Leading Anti-inflammatories, 2006
• 3.2 Anti-inflammatory Drug Sales by Indication
• 3.3 Immunomodulation is a Fast Growing Treatment Strategy
  • 3.3.1 The Anti-inflammatory Cytokines
• 3.4 AI Diseases with Biggest Impact on the Pharmaceutical Market

Chapter 4. The Balance between Inflammation and Immunity

• 4.1 Immunology of the Bowel
• 4.2 Adaptive Mucosal Immunity
• 4.3 Innate Mucosal Immunity
  • 4.3.1 Extracellular level
  • 4.3.2 Epithelial cell
  • 4.3.3 Sub-cellular level
• 4.4 Paneth Cells

Chapter 5. Inflammatory Bowel Disease IBD

• 5.1 Ulcerative Colitis and Crohn' s Disease
• 5.2 Aetiology of IBD
  • 5.2.1 Environmental Factors
  • 5.2.2 Genetic Predisposition
  • 5.2.3 Role of the Adaptive Immune System
  • 5.2.4 Role of the Innate Immune System
  • 5.2.5 Psychoneuroimmunology and Stress
• 5.3 Signs, Symptoms and Prognosis of IBD
  • 5.3.1 Characteristic Signs of IBD
    • 5.3.1.1 Ulcerative Colitis
    • 5.3.1.2 Crohn' s Disease
  • 5.3.2 Characteristic Symptoms of IBD
    • 5.3.2.1 Ulcerative Colitis
    • 5.3.2.2 Crohn' s Disease
  • 5.3.3 Characteristic Extra-intestinal Manifestations of IBD
  • 5.3.4 Prognosis of IBD
• 5.4 Diagnosis of IBD
  • 5.4.1 Differential Diagnosis of CD and UC
  • 5.4.2 Differential Diagnosis of IBD and Other Intestinal Diseases
• 5.5 Biological markers
  • 5.5.1 Faecal Calprotectin
  • 5.5.2 Lactoferrin
  • 5.5.3 ASCA and pANCA
• 5.6 Treatment Options for IBD
  • 5.6.1 General Supportive Therapy
  • 5.6.2 Aminosalicylates
  • 5.6.3 Leading Aminosalicylates
  • 5.6.4 Pentasa
  • 5.6.5 Colazal
  • 5.6.6 Dipentum
  • 5.6.7 Corticosteroids
  • 5.6.8 Immunomodulators
  • 5.6.9 Antibiotics
  • 5.6.10 Biological Immunomodulators
  • 5.6.11 TNF- alpha Antagonists
  • 5.6.12 Remicade
  • 5.6.13 Humira
  • 5.6.14 Enbrel

Chapter 6. The Potential Market for IBD Anti-inflammatories

• 6.1 World Prevalence Rates
  • 6.1.1 Environmental factors
  • 6.1.2 Gender and Age
• 6.2 Economic Burden of IBD
• 6.3 World IBD Anti-Inflammatory Market
  • 6.3.1 The US and Canada
  • 6.3.2 Europe - Germany, UK, Italy and France
  • 6.3.3 Central and South America
  • 6.3.4 Conclusions

Chapter 7. World Pharma Market for Intestinal Anti-inflammatories

• 7.1 The 5-ASAs Intestinal Anti-inflammatories
  • 7.1.1 World Leading Brand Aminosalicylates (5-ASAs)
  • 7.1.2 World leading Manufacturers- the Key Players
    • 7.1.2.1 Proctor & Gamble
    • 7.1.2.2 Ferring
    • 7.1.2.3 UCB
    • 7.1.2.4 Salix Pharmaceuticals
  • 7.1.3 Global Sales of Mesalazine
• 7.2 Future 5-ASA Market, 2007-2012
• 7.3 5-ASA Brand Forecasts, 2007-2012
  • 7.3.1 Asacol/ Salofalk
  • 7.3.2 Pentasa
  • 7.3.3 Colazal
  • 7.3.4 Azulfidine EN
  • 7.3.5 Dipentum
• 7.4 Anti-TNF- alpha Antagonists in 2006
  • 7.4.1 World Leading Brand Anti-TNF- alpha
• 7.5 Anti-TNF- alpha Biologicals, 2007-2012
  • 7.5.1 Remicade
  • 7.5.2 Humira

Chapter 8. Pipeline, Analysis and Effect on the Market

• 8.1 Main Pipeline Targets in Phase III
  • 8.1.1 Anti-TNF- alpha monoclonal antibodies
  • 8.1.2 Cytokine inhibitors
  • 8.1.3 Selective adhesion molecule antagonists
  • 8.1.4 Others
• 8.2 Market Pipelines for Anti-TNF- alpha Products
  • 8.2.1 Adalimumab - Humira from Abbott
  • 8.2.2 Certolizumab- Cimzia from UCB
  • 8.2.3 Etanercept - Enbrel from Amgen and Wyeth
  • 8.2.4 Onercept from Serono Merck
  • 8.2.5 CDP 571 from Biogen
  • 8.2.6 Thalidomide
  • 8.2.7 Mitogen Activated Protein Kinase
• 8.3 Market Pipeline for Other cytokine Inhibitors
  • 8.3.1 ABT-874 - Anti-IL-12 p40 Antibody from Abbott
  • 8.3.2 Tocilizumab- (MRA) Anti-IL-6 Antibody from Roche
  • 8.3.3 Daclizumab - Anti-IL-2 Receptor Antibody from Roche
  • 8.3.4 Basiliximab - Anti-IL-2 Receptor Antibody from Novartis
  • 8.3.5 Fontolizumab - Anti -IFN- gamma Antibody from Biopharma
• 8.4 Adhesion Molecule Inhibitors
  • 8.4.1 Natalizumab from Biogen Idec and Elan
  • 8.4.2 MLN-02 from Millennium Pharmaceuticals
  • 8.4.3 Alicaforsen (ISIS 2302)
• 8.5 Others
  • 8.5.1 Sargramostim (GM-CSF) Leukine from Schering
  • 8.5.2 Visilizumab from Nuvion and PDL Biopharma

Chapter 9. Conclusions

List of Figures

• 6.1 Prevalence Rates of IBD worldwide in 2004
• 6.2 World Intestinal Inflammatory Market by Revenues
• 6.3 World Intestinal Inflammatory Market by % Share
• 6.4 Revenues from the North American Intestinal Anti-inflammatory Market in 2005
• 6.5 Revenues from the European Intestinal Anti-inflammatory Market in 2005
• 6.6 Revenues from the Intestinal Anti-inflammatory Market in Latin America, 2005
• 7.1 Sales of Mesalazine Products during the 12 months to Q3, 2006
• 7.2 Share of the 5-ASA Market for IBD of Different Brands
• 7.3 Share of the Mesalazine Market for IBD of Different Brands
• 7.4 Growth of the 5-ASA Market Worldwide, 2007- 2012
• 7.5 5-ASA Product Revenues Worldwide, 2007-2012
• 7.6 Annual growth Rates for 5-ASAs Worldwide, 2007- 2012
• 7.7 Global Sales for Asacol/Salofalk, 2007-2012
• 7.8 AGR of Asacol and Salofalk, 2007-2012
• 7.9 Global Sales of Pentasa, 2007-2012
• 7.10 AGR for Pentasa, 2007-2012
• 7.11 Global Sales of Colazal, 2007-2012
• 7.12 AGR for Colazal
• 7.13 Global Sales of Azulfidine EN, 2007-2012
• 7.14 AGR of Azulfidine EN, 2007-2012
• 7.15 Forecast of Revenue from anti-TNF- alpha Products for the Period 2007-2012
• 7.16 World Revenues for Remicade, 2007- 2012
• 7.17 AGR for Remicade, 2007- 2012
• 7.18 World Revenues for Humira, 2007-2012
• 7.19 AGR for Humira, 2007-2012

List of Tables

• 2.1 Pro-inflammatory and Anti-inflammatory Cytokines
• 2.2 Spectrum of Autoimmune Disease
• 3.1 World Sales of Leading Prescription Anti-inflammatories, 2006
• 3.2 Leading Prescription Drugs by Disease Area for 2005
• 5.1 Treatment Algorithm for UC
• 5.2 Treatment Algorithm for CD
• 5.3 Brands Generating Highest Revenue Worldwide during 2006
• 7.1 The World Market for Asacol, 2007-2012
• 7.2 The Market for Salofalk, 2007-2012
• 7.3 The market for Pentasa, 2007-2012
• 7.4 The Market for Colazal, 2007- 2012
• 7.5 The Market for Azulfidine EN, 2007- 2012
• 7.6 Approved indications for the different anti-TNF- alpha biologicals
• 7.7 The World Market for Remicade by Revenue, 2005-2012
• 7.8 The World Market for Humira by Revenue, 2005-2012
• 7.9 Global Sales of Pentasa, 2007-2012
• 7.10 AGR for Pentasa, 2007-2012
• 7.11 Global Sales of Colazal, 2007-2012
• 7.12 AGR for Colazal
• 7.13 Global Sales of Azulfidine EN, 2007-2012
• 7.14 AGR of Azulfidine EN, 2007-2012
• 7.15 Forecast of Revenue from anti-TNF- alpha Products for the Period 2007-2012
• 7.16 World Revenues for Remicade, 2007- 2012
• 7.17 AGR for Remicade, 2007- 2012
• 7.18 World Revenues for Humira, 2007-2012
• 7.19 AGR for Humira, 2007-2012

Organisations Listed

• Abbott Laboratories
• Amgen
• Berlex Laboratories
• Biogen Idec
• Celltech
• Chugai pharmaceuticals
• Elan
• Dr Falk
• Ferring
• Genentech
• IVAX
• Johnson & Johnson
• Merck & Co
• Millennium Pharmaceuticals, Inc.
• Novartis
• PDL Biopharma
• Pfizer
• Pharmacia
• Procter & Gamble
• Schering-Plough
• Tanabe
• Teva Pharmaceutical Industries
• Roche
• Salix Pharmaceutical
• Sandoz
• Santen Pharmaceutical
• Sanofi-Aventis
• Serono
• Shire Pharmaceuticals Group
• UCB
• Wyeth

Related Reports